Strongbridge Biopharma (NASDAQ: SBBP) Starts Presentation at 29th Annual Roth Conference
Strongbridge Biopharma (NASDAQ: SBBP) is a biopharmaceutical company that focuses on the development, in-licensing, acquisition and commercialization of various complementary products and product candidates that target rare diseases in the United States and internationally. The company’s lead product candidate, COR-003 (levoketoconazole), is a cortisol inhibitor that is in the phase III trial for the treatment of endogenous Cushing’s syndrome. It is also developing COR-005 (veldoreotide), a novel somatostatin analog, which is in Phase II clinical development for the treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015.…







